source
- Immunotherapy startup Adecto shuts down, citing risk-averse funding climateAdecto Pharmaceuticals, a Boston-based immunotherapy biotech founded in 2014 by Tufts researchers, announced it is closing after 12 years. The company had been developing AD100, a monoclonal antib…
- Sanofi to pay $1 billion upfront to expand antibody partnership with RegeneronSanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration. The agreement is timed as the patent protection for Dupixent, the joi…